In his new position, Dr Nielsen, a founder of Merrimack who has been with the company since inception, continues to be responsible for the strategic direction of the company’s research, early stage pipeline products, new project ideas and discovering and encouraging techniques of integrating the network biology platform into therapeutic development from discovery stage through to the clinic.
Prior to joining Merrimack, Dr Nielsen was a post-doctoral fellow in Dr Peter Sorger’s laboratory at the Massachusetts Institute of Technology, where he researched the interface among biology, engineering, and computational biology.
Mr Stewart, who has been with the company since 2001, will continue to be responsible for the business development functions within the company including corporate partnering, licensing, intellectual property management and commercialization strategy.
Prior to joining Merrimack, Mr Stewart consulted on issues of product strategy to clients in the pharmaceutical, biotechnology and medical device industries. Mr Stewart holds a bachelor’s degree from Bates College and a MBA from the Johnson School at Cornell University.
Robert Mulroy, President and CEO of Merrimack, said: “Ulrik and Tad have both played critical roles in building Merrimack into the fully integrated and clinically diversified research and development company that we are today.”